Internal Medicine, Rheumatology · Palm Beach Gardens, FL
NPI
1659577831
Since 2007
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
3
Medicare group memberships
Hospitals
4
Hospital affiliations
7108 Fairway Dr Ste 300
Palm Beach Gardens, FL, 33418
Phone (561) 626-9696
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.0M
158,763 services
Medicare patients, 2024
1,079
Average age 77
Drug cost, 2024
$2.4M
3,729 prescriptions
Company payments, 2025
$1,079
From 6 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Paul D Mendoza was code J0717 (injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)), 56,200 times for 33 patients. In total Paul D Mendoza billed 158,763 services in 42 codes, and Medicare paid $2.0M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-01-31.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 56,200 | 33 | $3.62 | $203K |
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 27,092 | 44 | $8.58 | $232K |
| J0897 Injection, denosumab, 1 mg | Office | 18,722 | 250 | $20.60 | $386K |
| J3262 Injection, tocilizumab, 1 mg | Office | 16,331 | 14 | $4.70 | $77K |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 9,750 | 23 | $8.94 | $87K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 6,400 | 22 | $33.52 | $215K |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 4,111 | 264 | $0.75 | $3,098 |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 2,650 | 17 | $24.99 | $66K |
| 99214 Office E&M - Established | Office | 2,630 | 918 | $95.75 | $252K |
| J7322 Hyaluronan or derivative, hymovis, for intra-articular injection, 1 mg | Office | 2,472 | 25 | $13.70 | $34K |
| J9312 Injection, rituximab, 10 mg | Office | 2,054 | 12 | $61.04 | $125K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 2,043 | 864 | $12.80 | $26K |
| 96401 Chemotherapy Administration | Office | 726 | 316 | $57.28 | $42K |
| 20610 Joint Injection | Office | 508 | 141 | $42.09 | $21K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 474 | 12 | $0.23 | $107 |
By year: 2022 $2.0M for 153,454 services; 2023 $1.8M for 145,588 services; 2024 $2.0M for 158,763 services.
Medicare prescription drug claims, 2024
In 2024, the drug Paul D Mendoza prescribed most often to Medicare patients was Prednisone, with 557 prescriptions and refills. In total Paul D Mendoza wrote 3,729 Medicare prescriptions that cost $2.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prednisone Generic | 557 | 1,287 | 163 | $6,579 |
| Methotrexate Methotrexate Sodium | 439 | 1,126 | 135 | $14K |
| Hydroxychloroquine Sulfate Generic | 401 | 1,109 | 132 | $14K |
| Gabapentin Generic | 257 | 636 | 95 | $3,906 |
| Tramadol Hcl Generic | 177 | 203 | 31 | $1,284 |
| Alendronate Sodium Generic | 172 | 430 | 65 | $1,768 |
| Methylprednisolone Generic | 163 | 207 | 106 | $2,741 |
| Allopurinol Generic | 143 | 405 | 45 | $1,824 |
| Folic Acid Generic | 114 | 342 | 38 | $1,199 |
| Diclofenac Sodium Generic | 114 | 196 | 55 | $6,081 |
| Enbrel Sureclick Etanercept | 88 | 108 | Under 11 | $813K |
| Leflunomide Generic | 86 | 222 | 27 | $5,794 |
| Duloxetine Hcl Generic | 76 | 184 | 29 | $1,620 |
| Meloxicam Generic | 75 | 203 | 31 | $370 |
| Celecoxib Generic | 60 | 144 | 26 | $3,024 |
Brand drugs: 481 claims; generic drugs: 3,235 claims; opioid claims: 177.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Paul D Mendoza $1,079 ($1,079 in general payments such as food, travel and fees) from 6 companies. The largest payer was Novartis Pharmaceuticals Corporation with $454.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.